In silico design and search for acetylcholinesterase inhibitors in Alzheimer's disease with a suitable pharmacokinetic profile and low toxicity.
暂无分享,去创建一个
V. D. da Silva | Peterson de Andrade | D. Kawano | P. Morais | J. R. de Almeida | I. Carvalho | C. Taft | C. H. D. da Silva | C. D. da Silva
[1] J. Miller,et al. CARCINOGENESIS AND INHIBITION OF THE WALKER 256 TUMOR IN THE RAT BY TRANS-4-ACETYLAMINOSTILBENE, ITS N-HYDROXY METABOLITE, AND RELATED COMPOUNDS. , 1964, Cancer research.
[2] J. Seiler. The mutagenicity of benzimidazole and benzimidazole derivatives. II. Incorporation of benzimidazole into the nucleic acids of Escherichia coli. , 1973, Mutation research.
[3] H. Glatt,et al. Rat hepatocyte-mediated bacterial mutagenicity in relation to the carcinogenic potency of benz(a)anthracene, benzo(a)pyrene, and twenty-five methylated derivatives. , 1987, Cancer research.
[4] D A Basketter,et al. Possible origin of the skin sensitization potential of isoeugenol and related compounds , 1992, Contact dermatitis.
[5] J. Sussman,et al. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[6] F. Gage,et al. Cholinergic strategies for Alzheimer’s disease , 1998, Journal of Molecular Medicine.
[7] C. Guillou,et al. Potent acetylcholinesterase inhibitors: design, synthesis, and structure-activity relationships of bis-interacting ligands in the galanthamine series. , 1998, Bioorganic & medicinal chemistry.
[8] D A Basketter,et al. Classification criteria for skin‐sensitizing chemicals: a commentary , 1999, Contact dermatitis.
[9] A. Maelicke,et al. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer’s disease , 2000, Behavioural Brain Research.
[10] K. Goa,et al. Galantamine , 2000, Drugs.
[11] D Lamba,et al. Three‐dimensional structure of a complex of galanthamine (Nivalin®) with acetylcholinesterase from Torpedo californica: Implications for the design of new anti‐Alzheimer drugs , 2001, Proteins.
[12] M. Wolfe. Therapeutic strategies for Alzheimer's disease , 2002, Nature Reviews Drug Discovery.
[13] M. Citron. β‐secretase as a target for the treatment of Alzheimer's disease , 2002 .
[14] H. van de Waterbeemd,et al. ADMET in silico modelling: towards prediction paradise? , 2003, Nature reviews. Drug discovery.
[15] Richard D. Taylor,et al. Improved protein–ligand docking using GOLD , 2003, Proteins.
[16] Anabella Villalobos,et al. Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease. , 2004, European journal of pharmacology.
[17] R. Martins,et al. Age at onset: important marker of genetic heterogeneity in Alzheimer's disease , 2004, The Pharmacogenomics Journal.
[18] Thierry Langer,et al. Acetylcholinesterase inhibitory activity of scopolin and scopoletin discovered by virtual screening of natural products. , 2004, Journal of medicinal chemistry.
[19] J. Seiler. The molecular mechanism of benzimidazole mutagenicity: In vitro studies on transcription and translation , 1975, Biochemical Genetics.
[20] M. Rissel,et al. Toxic Effects of Tacrine on Primary Hepatocytes and Liver Epithelial Cells in Culture , 1998, Cell Biology and Toxicology.
[21] Richard M. Jackson,et al. Q-SiteFinder: an energy-based method for the prediction of protein-ligand binding sites , 2005, Bioinform..
[22] C. Caltagirone,et al. Guidelines for the Treatment of Alzheimer’s Disease from the Italian Association of Psychogeriatrics , 2005, Drugs & aging.
[23] J. Marco-Contelles,et al. Synthesis and pharmacology of galantamine. , 2006, Chemical reviews.
[24] V. Papadopoulos,et al. 3D QSAR studies of AChE inhibitors based on molecular docking scores and CoMFA. , 2006, Bioorganic & medicinal chemistry letters.
[25] M. Goedert,et al. A Century of Alzheimer's Disease , 2006, Science.
[26] J. Growdon,et al. Current pharmacotherapy for Alzheimer's disease. , 2006, Annual review of medicine.
[27] A. Maelicke,et al. The N-butylcarbamate derivative of galantamine acts as an allosteric potentiating ligand on alpha7 nicotinic receptors in hippocampal neurons: clinical implications for treatment of Alzheimer's disease. , 2006, Journal of molecular neuroscience : MN.
[28] Peter Willett,et al. GALAHAD: 1. Pharmacophore identification by hypermolecular alignment of ligands in 3D , 2006, J. Comput. Aided Mol. Des..
[29] T. Svensson,et al. Galantamine Enhances Dopaminergic Neurotransmission In Vivo Via Allosteric Potentiation of Nicotinic Acetylcholine Receptors , 2007, Neuropsychopharmacology.
[30] Ivone Carvalho,et al. Virtual Screening, Molecular Interaction Field, Molecular Dynamics, Docking, Density Functional, and ADMET Properties of Novel AChE Inhibitors in Alzheimer's Disease , 2007, Journal of biomolecular structure & dynamics.
[31] T. Nabeshima,et al. The Allosteric Potentiation of Nicotinic Acetylcholine Receptors by Galantamine Ameliorates the Cognitive Dysfunction in Beta Amyloid25–35 I.c.v.-Injected Mice: Involvement of Dopaminergic Systems , 2007, Neuropsychopharmacology.
[32] F. J. Luque,et al. New tacrine-dihydropyridine hybrids that inhibit acetylcholinesterase, calcium entry, and exhibit neuroprotection properties. , 2008, Bioorganic & medicinal chemistry.
[33] D. Holtzman. Alzheimer's disease: Moving towards a vaccine , 2008, Nature.
[34] Anshuman Dixit,et al. An investigation of structurally diverse carbamates for acetylcholinesterase (AChE) inhibition using 3D-QSAR analysis. , 2008, Journal of molecular graphics & modelling.